Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 9, 2006, Pages 793-797

  Yao, Hong Wei ^a   Mao, Lian Gen ^a   Zhu, Jian Ping ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute lung injury; Lipopolysaccharide; Pravastatin

Indexed keywords

ALBUMIN; EVANS BLUE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE; PRAVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; DRY WEIGHT; ENZYME ACTIVITY; LUNG HEMORRHAGE; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PNEUMONIA; STATISTICAL SIGNIFICANCE;

ALBUMINS; ANIMALS; ANTICHOLESTEREMIC AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; CYTOPROTECTION; DRUG EVALUATION, PRECLINICAL; LIPOPOLYSACCHARIDES; LUNG; MALE; MICE; MICE, INBRED BALB C; ORGAN SIZE; PEROXIDASE; PRAVASTATIN; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY FUNCTION TESTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33747073147     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04440.x     Document Type: Article

References (22)

1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N. Engl. J. Med. 2000; 342: 1334-49.
2. Wu Y, Singer M, Thouron F, Alaoui-El-Azher M, Touqui L. Effect of surfactant on pulmonary expression of type IIA PLA(2) in an animal model of acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 2002; 282: L743-50.
3. Kitamura Y, Hashimoto S, Mizuta N et al. Fas/FasL-dependent apoptosis of alveolar cells after lipopolysaccharide-induced lung injury in mice. Am. J. Respir. Crit. Care Med. 2001; 163: 762-9.
4. Anzueto A. Exogenous surfactant in acute respiratory distress syndrome: More is better. Eur. Respir. J. 2002; 19: 787-9.
5. Gerlach H, Keh D, Semmerow A et al. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: A prospective, randomized, controlled study. Am. J. Respir. Crit. Care Med. 2003; 167: 1008-15.
6. The ARDS Clinical Trials Network. Randomized placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit. Care Med. 2002; 30: 1-6.
7. Dellinger RP. Inhaled nitric oxide in acute lung injury and acute respiratory distress syndrome. Inability to translate physiologic benefit to clinical outcome benefit in adult clinical trials. Intensive Care Med. 1999; 25: 881-3.
8. van Nieuw Amerongen GP, Vermeer MA, Negre-Aminou P, Lankelma J, Emeis JJ, van Hinsbergh VW. Simvastatin improves disturbed endothelial barrier function. Circulation 2000; 102: 2803-9.
9. Kusama T, Mukai M, Iwasaki T et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002; 122: 308-17.
10. Fassbender K, Simons M, Bergmann C et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 2001; 98: 5856-61.
11. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001; 32: 980-6.
12. Jacobson JR, Dudek SM, Birukov KG et al. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am. J. Respir. Cell Mol. Biol. 2004; 30: 662-70.
13. Peng X, Hassoun PM, Sammani S et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am. J. Respir. Crit. Care Med. 2004; 169: 1245-51.
14. Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JG. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 2005; 288: L1026-32.
15. Mikawa K, Nishina K, Takao Y, Obara H. ONO-1714, a nitric oxide synthase inhibitor, attenuates endotoxin-induced acute lung injury in rabbits. Anesth. Analg. 2003; 97: 1751-5.
16. de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am. J. Respir. Crit. Care Med. 2003; 167: 490-511.
17. Shimoyama T, Tabuchi N, Kojima K et al. Aprotinin attenuated ischemia-reperfusion injury in an isolated rat lung model after 18-hours preservation. Eur. J. Cardiothorac. Surg. 2005; 28: 581-7.
18. Joyce M, Kelly CJ, Chen G, Bouchier-Hayes DJ. Pravastatin attenuates lower torso ischaemia-reperfusion-induced lung injury by upregulating constitutive endothelial nitric oxide synthase. Eur. J. Vasc. Endovasc. Surg. 2001; 21: 295-300.
19. Renkin EM, Tucker VL. Measurement of microvascular transport parameters of macromolecules in tissues and organs of intact animals. Microcirculation 1998; 5: 139-52.
20. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
21. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446-52.
22. Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur. J. Pharmacol. 2000; 410: 83-92.